Inpatient Outcomes for Myocarditis-Related Heart Failure

Mohammad Alabbas1, Cheryl Gibson2, Abdulrahman Morad3

  • 1Internal Medicine, University of Debrecen, Debrecen, Hungary.

PubMed

Insights

Myocarditis-associated heart failure (HF) leads to worse outcomes, including higher inpatient mortality and longer hospital stays compared to HF without myocarditis. This highlights the critical impact of myocarditis on HF patient prognosis.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Public Health

Background:

  • Heart failure (HF) is a major cause of hospitalization and mortality in the US.
  • Myocarditis is an understudied cause of HF with significant implications.

Purpose of the Study:

  • To compare inpatient outcomes between HF patients with and without myocarditis.
  • To understand the specific impact of myocarditis on HF patient prognosis and resource utilization.

Main Methods:

  • Utilized the Nationwide Readmissions Database (2016-2019) for adult HF admissions.
  • Compared outcomes between HF without myocarditis and myocarditis-associated HF (MAHF) using propensity score-weighted models.
  • Applied survey procedures and SAS 9.4 for statistical analysis.

Main Results:

  • MAHF patients were younger (53 vs. 72 years) and had fewer women (45% vs. 48%).
  • MAHF cases experienced more inpatient complications (cardiac arrest, cardiogenic shock, mechanical support) despite fewer comorbidities.
  • MAHF was associated with longer hospital stays (9.2 vs. 5.5 days) and significantly higher in-hospital mortality (3.9% vs. 2.8%).

Conclusions:

  • Myocarditis-associated HF significantly increases inpatient mortality.
  • MAHF leads to greater resource utilization and prolonged hospitalizations.
  • Myocarditis is a critical predictor of inpatient mortality in heart failure patients.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
161